磷脂复合物改善丹参素口服生物利用度的研究
Study on Phospholipid Complex Improving Oral Danshensu Bioavailability
-
摘要: 目的 考察丹参素磷脂复合物在大鼠体内的药动学特性,并与丹参素原料药进行比较。方法 灌胃给予大鼠丹参素和丹参素磷脂复合物(含丹参素等量),LC-MS/MS法测定大鼠血浆中丹参素的浓度,通过DAS2.1.1软件计算药动学参数。结果 丹参素组Cmax为(1.28±0.13)×103ng/mL,Tmax为(51±8.22) min,AUC0-t为(2.05±0.24)×105 ng/(mL·min);丹参素磷脂复合物组Cmax为(1.88±0.07)×103 ng/mL,Tmax为(90±18.37) min,AUC0-t为(3.07±0.50)×105ng/(mL·min)。结论 磷脂复合物能够增加丹参素的口服生物利用度。Abstract: OBJECTIVE To explore pharmacokinetic features of Danshensu phospholipid complex(DPLC) in rats and compare with Danshensu APIs. METHODS Danshensu and DPLC (containing the same amount of Danshensu) were taken in intragastric administration.The concentration of Danshensu in plasma was detected in LC-MS/MS method while pharmacokinetic parameters were calculated with DAS 2.1.1 software. RESULTS In Danshensu group, C max was(1.28±0.13)×103 ng/mL,T max was (51±8.22) min,AUC 0-t was (2.05±0.24)×105 ng/(mL·min);in DPLC group, C max was (1.88±0.07)×103 ng/mL,T maxwas (90±18.37) min,AUC 0-t was (3.07±0.50)×105 ng/(mL·min). CONCLUSION Phospholipid complex can increase oral Danshensu bioavailability.
-
Key words:
- Danshensu /
- phospholipid complex /
- bioavailability
-
[1] 方杰.丹参素对乳腺癌MCF细胞株的作用[J].中国老年学杂志,2003, 23(3):168-169. [2] Fang J.Effects of Danshensu on breast cancer cell lines MCF[J]. Chin J Gerontol, 2003, 23(3): 168-169. [3] 周鑫,韩德五,尹镭,等.丹参素保护肝损伤作用及其作用机制的实验研究[J].山西医药杂志,2006, 35(2):108-110. [4] Zhou X, Han DW, Yin L, et al. Protective role of Danshensu in liver injury rats and its pathogenesis[J]. Shanxi Med J, 2006, 35(2): 108-110. [5] 李骅,王四旺,张邦乐,等.丹参素的药理活性与药物动力学研究进展[J].西北药学杂志,2011, 26(4):310-312. [6] Li H, Wang SW, Zhang BL, et al. Pharmacological action and pharmacokinetics of danshensu[J]. Northwest Pharm J, 2011, 26(4): 310-312. [7] Bombardelli E. Phytosome: new cosmetic delivery system[J]. Boll Chim Farm, 1991, 130(11): 431-438. [8] 刘伟.奥沙利铂磷脂复合物的制备及其在静脉给药剂型中的应用研究[D].沈阳:沈阳药科大学,2006. [9] Liu W. Investigation on the preparation of oxaliplatin phospholipid complex and its application in intravenous delivery system[D]. Shenyang: Shenyang pharmaceutical university,2006. [10] 刘嘉,李俊松,狄留庆,等.丹酚酸B及其磷脂复合物在SD大鼠的生物利用度研究[J].中国药学杂志,2010, 45(18):1408-1411. [11] Liu J, Li JS, Di LQ, et al. Study on bioavailability of Salvianolic acid B and its phospholipid complex in SD rats[J]. Chin Pharmacol J, 2010, 45(18): 1408-1411. [12] 甘美婵.丹红口腔崩解片的制剂及其药代动力学研究[D].武汉:华中科技大学,2009. [13] Gan MC. Study on preparation and pharmacokinetics of Danhong orally disintegrating tablets[D]. Wuhan: Huazhong university of science and technology,2009. [14] 张丽琼,廖敏华,李明生,等.丹参静脉注射后在兔血浆和眼玻璃体中的药代动力学研究[J].哈尔滨医科大学学报,2012, 46(5):415-419. [15] Zhang LQ, Liao MH, Li MS, et al. Pharmacokinetic research of Salvia miltiorrhiza in rabbits plasma and vitreous body after intravenous injection[J]. J Harbin Med Univ, 2012, 46(5): 415-419. [16] 潘桂湘,张伯礼,高秀梅.大鼠灌服复方丹参方后血清中丹参素的测定[J].中国中药杂志,2003, 28(6):562-565. [17] Pan GX, Zhang BL, Gao XM. Determination of danshensu in rat serum after oral administer compound salvia recipe[J]. China J Chin Mater Med, 2003, 28(6): 562-565. [18] Li W, Li ZW, Han JP, et al. Determination and pharmacokinetics of danshensu in rat plasma after oral administration of danshen extract using liquid chromatography/tandem mass spectrometry[J]. Eur J Drug Metab Pharmacokinet, 2008, 33(1): 9-16.
点击查看大图
计量
- 文章访问数: 917
- HTML全文浏览量: 9
- PDF下载量: 1008
- 被引次数: 0